A case series of dupilumab-treated atopic dermatitis resulting in new onset psoriasis

Five male patients age ranged from 30-69 were each diagnosed with moderate-to-severe AD. They were initially treated with traditional topical and systemic therapies for atopic dermatitis such as topical steroids, calcineurin inhibitors, and oral immune suppressants. Ultimately, all patients required dupilumab with improvement noted in their first few months of treatment. Psoriaform dermatitis presented at varying timelines. In 4/5 cases, the diagnosis of presumed druginduced psoriasis was supported with biopsies and pathology consistent with the morphologic changes noted in clinic (Figure 1). In 4/5 cases patients were able to fully recover from psoriaform plaques when dupilumab was discontinued. In some cases, patients were able to restart Dupilumab without reoccurrence of psoriaform findings. However, in one case, the rash persisted despite several treatment attempts. (Table 2).